Lawrence Tenkman, MD
Ophthalmology · Louisville, KYNPI 1023207859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Alcon at 43.1% of the total.
Across 207 payments — averaging $24.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$493
- AbbVie$468
- Tarsus Pharmaceuticals, Inc.$256
- Ocular Therapeutix, Inc.$203
- Biotissue Holdings Inc.$163
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,99799%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 86 | $2,173 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $493 |
| AbbVie(2 entities) | 16 | $468 |
| Tarsus Pharmaceuticals, Inc. | 5 | $256 |
| Ocular Therapeutix, Inc. | 14 | $203 |
| Biotissue Holdings Inc. | 9 | $163 |
| Sun Pharmaceutical Industries Inc. | 4 | $159 |
| Mallinckrodt Hospital Products Inc. | 4 | $135 |
| NEW World Medical,inc. | 7 | $112 |
| Omeros Corporation | 7 | $94 |
| Glaukos Corporation | 4 | $81 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $78 |
| Sight Sciences, Inc. | 4 | $73 |
| Bausch & Lomb Americas Inc. | 3 | $66 |
| Ivantis, Inc | 4 | $54 |
| Novartis | 3 | $53 |
| Dompe US, Inc. | 3 | $44 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Eyevance Pharmaceuticals LLC | 3 | $39 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Rayner Intraocular Lenses Limited | 2 | $38 |
| Rxsight Inc | 2 | $37 |
| Amgen | 2 | $31 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Harrow Eye, LLC | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $13 |
| Lombart Brothers, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$148
- ReSTOR$125
- Clareon PanOptix Pro$125
- XDEMVY$125
- Hydrus Microstent$115
- Clareon$109
- AcrySof IQ PanOptix UV IOL$108
- AcrySof IQ VIVITY$108
- XEN$108
- CEQUA$106
- Tecnis IOL$105
How this compares
$5,042 in reported general payments places this provider in the 80th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 521 | $22,362 |
| RestasisCyclosporine | 27 | $15,958 |
| RhopressaNetarsudil Mesylate | 30 | $10,941 |
| MoxifloxacinMoxifloxacin Hcl | 315 | $10,738 |
| RocklatanNetarsudil Mesylat/Latanoprost | 26 | $9,293 |
| LumiganBimatoprost | 31 | $7,619 |
| Lotemax SmLoteprednol Etabonate | 23 | $5,872 |
| ZirganGanciclovir | 12 | $5,671 |
| Loteprednol Etabonate | 51 | $5,262 |
| Difluprednate | 33 | $5,120 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $4,764 |
| Fluorometholone | 42 | $3,215 |
| Ketorolac Tromethamine | 88 | $2,027 |
| Atropine Sulfate | 43 | $1,470 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 92 | $1,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $468 | $28,34179 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $38 | $20,23456 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $78 | $11,13474 claims |
| Bausch & Lomb Americas Inc.Zirgan | $66 | $5,67112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Louisville
- Jeremy ClarkLouisville$131K
- Guruprasad PattarLouisville$36K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Inder SingalLouisville$9K
- Rishi KumarLouisville$8K
- Frank BurnsLouisville$8K
- Steven BloomLouisville$6K
- Sharmini BalakrishnanLouisville$6K
- Sergei DmitrukLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.